PCRX Q1 2020 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$106M+15.7% YoY

Gross Profit

$76M71.9% margin

Operating Income

$17M16.2% margin

Net Income

$8M7.7% margin

EPS (Diluted)

$0.19

QoQ Revenue Growth

-13.7%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

-$516,000

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$821M

Total Liabilities

$447M

Stockholders' Equity

$374M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$106M	$91M	+15.7%
Gross Profit	$76M	$64M	+18.7%
Operating Income	$17M	$1M	+1484.2%
Net Income	$8M	-$3M	+394.4%

Revenue Segments

Product

$105M99%

Royalty

$939,0001%